anti-bFGF MAb (DuPont)

N/A

Report date: 2025/03/18 20:00:05

Base Information

Drug Nameanti-bFGF MAb (DuPont)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment

Mechanisms of ActionFibroblast growth factor 2 inhibitors

TargetsFibroblast growth factor 2

Therapy Area/IndicationsAngiogenesis disorder

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesBristol-Myers Squibb Pharma Company

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBristol-Myers Squibb Pharma Company

Active IndicationsN/A

Inactive IndicationsAngiogenesis disorder

Other Information

ATC CodeN/A